SAN DIEGO, Sept. 16, 2026 /PRNewswire/ — Halozyme Therapeutics, Inc. (Nasdaq: HALO) (“Halozyme” or the “Company”), today announced that it intends to offer, subject to market conditions and other factors, $1.05 billion aggregate principal amount of convertible senior notes due 2033 (the…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
